Fig 1: IFN? induces upregulation of MHC-II in LECs in vitro and in vivo in the tumor periphery. (A–D) Relative mRNA expression of HLA-DRA, HLA-DM, PD-L1, LYVE-1 in cultured human dermal LECs after 24-h treatment with (A) IFN? (100 ng/mL), (B) VEGF-C (100 ng/mL), (C) IL-2 (10 ng/mL) and (D) TNF-a (10 ng/mL). (E) Representative FACS histogram plot and (F) quantification of MHC-II and PD-L1 positive human dermal LECs in culture after 24-hour treatment with IFN? (100 ng/mL) as measured by flow cytometry. (G) Representative FACS histogram plots and (H) quantification of MHC-II and PD-L1 positive peritumoral LECs in WT mice treated with IFN? neutralizing antibody or IgG isotype control at day 14 post tumor inoculation. Statistical significance assessed using unpaired student’s t test on data from at least 3 biological replicates for cell culture studies and at least 4 biological replicates for mouse experiments; statistical analysis not performed on (B–D) for which at least 2 biological replicates were used; error represented as SD. *, p < 0.05; **, p < 0.01; ***, p < 0.001. n.d, not detected mRNA in treated group.